ivonescimab
Summit Therapeutics
['summit', 'nsclc', 'sclc', 'ivonescimab']
$smmt -promising data for investigational innovative bispecific ivonescimab featured at asco 2023 data supporting summit s planned phase iii trial for first-line metastatic squamous nsclc patients on display phase ii orr of 67% with a mdor of 15 months in 1l sq-nsclc patients
Full-time trader. My tweets are ideas & opinions. Don't trade based on them. Read Reminiscences of a Stock Operator.